Identification and isolation of antibodies against pathogenic bacteria in healthy blood donors and infected patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00036974

Enrollment

2200

Registered

2025-05-23

Start date

2025-06-23

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antibacterial antibodies

Interventions

Group 1: Identification of antibacterial antibodies in sera from cystic fibrosis patients. Isolation of such antibodies by single cell sorting of B cells after isolation of PBMC after blood collection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Cystic fibrosis diagnosis OR infection with resistant bacteria OR healthy blood donor, clinically stable, able to give consent

Exclusion criteria

Exclusion criteria: incapable of giving consent, under 18 years old, clinically unstable

Design outcomes

Primary

Measure	Time frame
Production of monoclonal antibacterial antibodies	—

Secondary

Measure	Time frame
Gender-specific or age-specific differences in the effect of the antibodies, presence of natural antibacterial antibodies, comparison of the groups with regard to the effectiveness of the antibodies in vitro	—

Countries

Germany

Contacts

Public ContactLaura Thümmler

Universitätsklinikum Essen

laura.thuemmler@uk-essen.de+49 201 723 82939

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026